Praxis Precision Medicines
PRAX255.0251.50% ( -3.895 )
Trading: Oct 23, 12:58:50 (EDT)Praxis Precision Medicine Q2 2026 Earnings Call Transcript
benzinga_article·Analyst Reiterates Buy on PRAX with Unchanged $582 Price Target Ahead of Key Phase 3 EMERALD Trial for Relutrigine
Tip Ranks·- Needham analyst Ami Fadia reaffirmed a buy rating on Praxis Precision Medicines with a target price of $ 582.00 ahead of the Phase III EMERALD trial for relutrigine expected in Q 4 2026. - The rating is supported by strong efficacy signals in SCN 2 A and SCN 8 A patients, supportive preclinical evidence, and conservative market pricing relative to high unmet medical needs. - Positive trial results could expand relutrigine's peak sales potential from approximately $ 1.5 billion to about $ 5 billion.McKesson Buy Rating Reiterated as Precision Medicine Acquisition Strengthens Oncology Platform; $1050 Price Target Unchanged
Tip Ranks·- Bank of America Securities analyst Allen Lutz reaffirmed a buy rating on McKesson with an unchanged price target of $ 1050 on August 18. - The rating is supported by McKesson's strategic acquisition of Precision Medicine Group, which enhances its oncology platform and early drug development capabilities. - Barclays also maintained a buy rating on the stock with a price target of $ 1000.00 in a separate report issued on the same day.